Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group

키워드

참고문헌 (45)

1. Cagle PT, "Advances in treatment of lung cancer with targeted therapy", Arch Pathol Lab Med, 136, pp.504~509 (2012)
2. Janku F, "Targeted therapy in non-small-cell lung cancer: is it becoming a reality?", Nat Rev Clin Oncol, 7, pp.401~414 (2010)
3. Linardou H, "Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC", Nat Rev Clin Oncol, 6, pp.352~366 (2009)
4. Mok TS, "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N Engl J Med, 361, pp.947~957 (2009)
5. Fukuoka M, "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin", paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS), 2011, pp.29, 2866~2874
6. D’Angelo SP, "Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas", J Clin Oncol, 29, pp.2066~2070 (2011)
7. Sun PL, "High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR", TTF- 1 expressions, and clinical features, 2012, pp.7, 323~330
8. Pirker R, "Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop", J Thorac Oncol, 5, pp.1706~1713 (2010)
9. Travis WD, "International Association for the Study of Lung Cancer", American Thoracic Society, J Thorac Oncol, pp.2011, 6[DOI]
10. Salto-Tellez M, "Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach", J Thorac Oncol, 6, pp.1663~1669 (2011)
11. Rekhtman N, "Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens", Mod Pathol, 24, pp.1348~1359 (2011)
12. Noh S, "Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: a tissue microarray study of poorly differentiated areas", Lung Cancer, 76, pp.51~55 (2012)
13. Yatabe Y, "EGFR mutations and the terminal respiratory unit", Cancer Metastasis Rev, 29, pp.23~36 (2010)
14. Zakowski MF, "Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib", Arch Pathol Lab Med, 133, pp.470~477 (2009)
15. Shim HS, "Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer", American Thoracic Society, Arch Pathol Lab Med, pp.2011, 135[DOI]
16. 박세훈, "Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung", Journal of Korean Medical Science, 24(3), pp.448~452 (2009), 대한의학회
17. Miyamae Y, "Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma", Oncol Rep, 25, pp.921~928 (2011)
18. Tatematsu A, "Epidermal growth factor receptor mutations in small cell lung cancer", Clin Cancer Res, 14, pp.6092~6096 (2008)
19. Shiao TH, "Epidermal growth factor receptor mutations in small cell lung cancer: a brief report", J Thorac Oncol, 6, pp.195~198 (2011)
20. Rekhtman N, "Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing", J Thorac Oncol, 6, pp.451~458 (2011)
21. Navani N, "Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients", Am J Respir Crit Care Med, 185, pp.1316~1322 (2012)
22. Allegrini S, "Epidermal growth factor receptor gene analysis with a highly sensitive molecular assay in routine cytologic specimens of lung adenocarcinoma", Am J Clin Pathol, 138, pp.377~381 (2012)
23. Sun PL, "High concordance of EGFR mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas", Cancer Cytopathol (2012)
24. da Cunha Santos G, "EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities", Cancer Cytopathol, 119, pp.80~91 (2011)
25. Taniguchi K, "Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib", Cancer Sci, 99, pp.929~935 (2008)
26. Schmid K, "EGFR", KRAS, Clin Cancer Res, pp.2009, 15[DOI]
27. Gow CH, "Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer", Ann Oncol, 20, pp.696~702 (2009)
28. Yatabe Y, "Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma", J Clin Oncol, 29, pp.2972~2977 (2011)
29. Chen ZY, "EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas", Oncologist, 17, pp.978~985 (2012)
30. Bai H, "Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer", J Clin Oncol, 30, pp.3077~3083 (2012)
31. Eberhard DA, "Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting", J Clin Oncol, 26, pp.983~994 (2008)
32. Nicholson AG, "Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5", 6, and p63, and EGFR mutation analysis, 2010, pp.5, 436~441
33. Pao W, "Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method", Clin Cancer Res, 13, pp.4954~4955 (2007)
34. Ellison G, "EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples", J Clin Pathol, 66, pp.79~89 (2013)
35. 정진행, "Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment", Journal of Pathology and Translational Medicine, 47(1), pp.52~60 (2013), 대한병리학회
36. 김희정, "EGFR 돌연변이 검출에 있어 PNA-Mediated Real-Time PCR Clamping과 직접 염기서열 분석법의 비교 분석", Tuberculosis and Respiratory Diseases, 70(1), pp.21~27 (2011), 대한결핵및호흡기학회
37. Kim HJ, "Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer", Lung Cancer, 75, pp.321~325 (2012)
38. Han HS, "Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity", J Thorac Oncol, 7, pp.355~364 (2012)
39. Arcila ME, "Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay", Clin Cancer Res, 17, pp.1169~1180 (2011)
40. van Krieken JH, "KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program", Virchows Arch, 453, pp.417~431 (2008)
41. Bergethon K, "ROS1 rearrangements define a unique molecular class of lung cancers", J Clin Oncol, 30, pp.863~870 (2012)
42. Marchetti A, "Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations", J Clin Oncol, 29, pp.3574~3579 (2011)
43. Paik PK, "Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations", J Clin Oncol, 29, pp.2046~2051 (2011)
44. Arcila ME, "Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas", Clin Cancer Res, 18, pp.4910~4918 (2012)
45. Wang R, "RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer", J Clin Oncol, 30, pp.4352~4359 (2012)

관련 논문AI추천